Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Shattuck Labs, Inc. (STTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights –Presented complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer at the American Society of Clinical Oncology 2023 annual meeting, including data supporting 3 mg/kg as the appropriate dose for each PROC combination cohort –"
05/24/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights –Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer to be presented at the 2023 American Society of Clinical Oncology annual meeting in June –"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
02/23/2023 8-K Quarterly results
Docs: "Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates –Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –"
11/08/2022 8-K Quarterly results
Docs: "Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights –Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer&#59; complete data expected midyear 2023 –"
08/11/2022 8-K Quarterly results
07/29/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, between Shattuck Labs, Inc. and SVB Securities LLC",
"Opinion of Gibson, Dunn & Crutcher LLP"
06/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights – Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients –"
11/09/2021 8-K Quarterly results
Docs: "Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights – Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer annual meeting&#59; both clinical trials remain ongoing –"
10/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Shattuck Labs Announces Changes to its Board of Directors"
08/11/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
10/14/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy